What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?
What Does Dental Player Patterson's $4.1 Billion Deal Mean For Other Players?
Additionally, the analyst's dental valuation analysis suggests the offer for Patterson is strong, making it unlikely that higher bids will emerge during the 40-day window for competing offers.On Wednesday, Patient Square Capital, a healthcare investment firm, agreed to acquire Patterson Companies, Inc. (NASDAQ:PDCO), a dental and animal health product distributor, for approximately $4.1 billion.
在周三，医疗投资公司Patient Square Capital同意收购帕特森公司（纳斯达克：PDCO），这是一家牙科和动物健康产品分销商，交易金额约为41亿美金。
During its second-quarter earnings release, the company announced it is exploring strategic options, including a sale or merger, to boost shareholder value.
在其第二季度盈利报告中，公司宣布正在探索战略选择，包括出售或合并，以提升股东价值。
William Blair notes that based on Patient Square Capital's portfolio, which doesn't include dental or animal health companies, regulatory hurdles for this deal are unlikely.
William Blair指出，基于Patient Square Capital的投资组合，其中不包括牙科或动物健康公司，因此该交易的监管障碍不太可能出现。
Additionally, the analyst's dental valuation analysis suggests the offer for Patterson is strong, making it unlikely that higher bids will emerge during the 40-day window for competing offers.
此外，分析师的牙科估值分析表明，帕特森的报价强劲，因此在40天的竞争性报价窗口期内不太可能出现更高的出价。
The valuation analysis includes Align Technology Inc (NASDAQ:ALGN), Dentsply Sirona Inc (NASDAQ:XRAY), Henry Schein Inc (NASDAQ:HSIC), Envista Holdings Corporation (NYSE:NVST) and Europe-listed Straumann Holding.
估值分析包括Align Technology Inc (纳斯达克:ALGN)、登士柏 Inc (纳斯达克:XRAY)、汉瑞祥 Inc (纳斯达克:HSIC)、Envista Holdings Corporation (纽交所:NVST)以及在欧洲上市的Straumann Holding。
William Blair writes that most dental companies they cover are trading at or near their lowest valuations in 15 years, as investor interest has declined due to ongoing macroeconomic challenges.
William Blair写道，他们关注的大多数牙科公司交易价格已接近15年来的最低估值，因投资者兴趣因持续的宏观经济挑战而下降。
Most recently, Dentsply Sirona revised its 2024 outlook due to market pressures impacting U.S. equipment, legislative changes affecting the direct-to-consumer aligner business model, and the voluntary suspension of sales, marketing, and shipments of Byte Aligners and Impression Kits.
最近，登士柏修订了其2024年展望，原因是市场压力影响美国设备，立法变化影响直接面向消费者的矫正器商业模式，以及自愿暂停Byte Aligners和印象工具的销售、市场推广和发货。
Henry Schein's third-quarter global dental segment sales were $1.9 billion, down 1.6%, and medical segment sales increased by 2.9% (down 4.8% internally) to $1.1 billion.
汉瑞祥第三季度全球牙科部门销售额为19亿美金，下降了1.6%，医疗部门销售额增长了2.9%（内部下降4.8%），达到了11亿美金。
While it's still early to gauge investor reactions, the analyst is considering whether Patterson's acquisition might stabilize valuations and boost demand in the dental sector.
虽然现在还早，无法评估投资者的反应，但分析师正在考虑帕特森的收购是否可能稳定估值并提升医疗板块的需求。
The analyst writes the move could support valuations and signal a potential recovery in the market, making many dental stocks appealing from a risk/reward perspective.
分析师写道，此举可能支持估值，并暗示市场的潜在复苏，使得许多医疗股票在风险/回报方面变得更加吸引人。
Among these, William Blair sees Align as having the greatest potential for stock growth, driven by improving market conditions and gains in both earnings and valuation.
在这些股票中，威廉·布莱尔认为Align具有最大的股票增长潜力，得益于市场条件的改善以及收益和估值的增长。
- Gevo And LG Chem Double Down On Ethanol-To-Olefins Tech: Details
- Gevo与LG化学在乙醇转烯烃技术方面加大投入：详情
Photo via Shutterstock
图片来自shutterstock
